Choice of compound, dosage, and management of side effects for long-term corticosteroid treatment in Duchenne muscular dystrophy: Guidelines from the Neuromuscular Commission of the French Society of Pediatric Neurology - 19/10/24
, Ivana Dabaj b, Camille de Montferrand a, Pascal Rippert c, Vincent Laugel d, Silvana De Lucia e, Claudia Ravelli e, Andreea Seferian e, Juliette Ropars f, Claude Cances gAbstract |
The French Society of Pediatric Neurology and the FILNEMUS network created a working group on corticosteroid therapy in children with Duchenne muscular dystrophy in order to analyze the literature review and current French practices. The aim of this work was to produce guidelines regarding treatment initiation, pre-therapeutic interventions, choice between available compounds, and treatment monitoring (dosage, duration, and discontinuation). The treatment side effects and their management are also detailed: osteoporosis, endocrinological anomaly (growth delay, weight gain, pubertal delay), cataract, arterial hypertension, behavioral disorders, management of immunosuppression and vaccines, and management of gastrointestinal and metabolic complications.
Le texte complet de cet article est disponible en PDF.Keywords : Duchenne muscular dystrophy, Glucocorticoids, Drug therapy
Plan
Vol 31 - N° 7
P. 410-418 - octobre 2024 Retour au numéro
Article précédent
- Neonatal screening: A public health success and the ethical dilemmas it can pose
- Brigitte Chabrol
- Immediate allergies to chlorhexidine: A series of pediatric cases from the French pharmacovigilance database : Immediate allergies to chlorhexidine: series of pediatric cases from the French pharmacovigilance database
- Claire Fontaine, Cécile Rochefort-Morel, Gwenaëlle Veyrac, Elisabeth Polard, Lucie-Marie Scailteux, French Pharmacovigilance Network
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?